Trade Vor Biopharma Inc. - VOR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 1.82 |
Open* | 1.76 |
1-Year Change* | -61.23% |
Day's Range* | 1.76 - 1.96 |
52 wk Range | 1.62-7.57 |
Average Volume (10 days) | 196.00K |
Average Volume (3 months) | 2.30M |
Market Cap | 119.34M |
P/E Ratio | -100.00K |
Shares Outstanding | 67.81M |
Revenue | N/A |
EPS | -1.89 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Mar 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 1.91 | 0.15 | 8.52% | 1.76 | 1.97 | 1.76 |
Nov 30, 2023 | 1.82 | 0.06 | 3.41% | 1.76 | 1.84 | 1.71 |
Nov 29, 2023 | 1.78 | -0.02 | -1.11% | 1.80 | 1.86 | 1.73 |
Nov 28, 2023 | 1.79 | -0.02 | -1.10% | 1.81 | 1.88 | 1.78 |
Nov 27, 2023 | 1.86 | 0.06 | 3.33% | 1.80 | 1.87 | 1.79 |
Nov 24, 2023 | 1.79 | 0.03 | 1.70% | 1.76 | 1.84 | 1.76 |
Nov 22, 2023 | 1.74 | -0.04 | -2.25% | 1.78 | 1.78 | 1.66 |
Nov 21, 2023 | 1.75 | 0.08 | 4.79% | 1.67 | 1.79 | 1.60 |
Nov 20, 2023 | 1.66 | -0.09 | -5.14% | 1.75 | 1.75 | 1.61 |
Nov 17, 2023 | 1.73 | -0.02 | -1.14% | 1.75 | 1.77 | 1.70 |
Nov 16, 2023 | 1.73 | -0.04 | -2.26% | 1.77 | 1.79 | 1.65 |
Nov 15, 2023 | 1.76 | -0.14 | -7.37% | 1.90 | 1.95 | 1.75 |
Nov 14, 2023 | 1.89 | 0.09 | 5.00% | 1.80 | 1.91 | 1.78 |
Nov 13, 2023 | 1.77 | 0.04 | 2.31% | 1.73 | 1.78 | 1.68 |
Nov 10, 2023 | 1.73 | -0.18 | -9.42% | 1.91 | 1.98 | 1.73 |
Nov 9, 2023 | 1.83 | 0.04 | 2.23% | 1.79 | 1.88 | 1.68 |
Nov 8, 2023 | 1.83 | -0.08 | -4.19% | 1.91 | 1.94 | 1.81 |
Nov 7, 2023 | 1.96 | 0.11 | 5.95% | 1.85 | 1.98 | 1.77 |
Nov 6, 2023 | 1.81 | -0.09 | -4.74% | 1.90 | 1.99 | 1.75 |
Nov 3, 2023 | 1.86 | 0.07 | 3.91% | 1.79 | 1.88 | 1.62 |
Vor Biopharma Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, December 5, 2023 | ||
Time (UTC) 18:30 | Country US
| Event Vor Biopharma Inc at JMP Securities Hematology and Oncology Summit (Virtual) Vor Biopharma Inc at JMP Securities Hematology and Oncology Summit (Virtual)Forecast -Previous - |
Thursday, March 21, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 Vor Biopharma Inc Earnings Release Q4 2023 Vor Biopharma Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 93.418 | 69.018 | 43.366 | 10.417 | 2.86 |
Selling/General/Admin. Expenses, Total | 28.868 | 21.489 | 11.748 | 4.217 | 0.427 |
Research & Development | 64.55 | 47.529 | 31.618 | 6.2 | 2.433 |
Operating Income | -93.418 | -69.018 | -43.366 | -10.417 | -2.86 |
Interest Income (Expense), Net Non-Operating | 1.324 | 0.119 | 0.029 | -0.422 | -1.292 |
Net Income Before Taxes | -92.094 | -68.899 | -43.337 | -10.839 | -4.152 |
Net Income After Taxes | -92.094 | -68.899 | -43.337 | -10.839 | -4.152 |
Net Income Before Extra. Items | -92.094 | -68.899 | -43.337 | -10.839 | -4.152 |
Net Income | -92.094 | -68.899 | -43.337 | -10.839 | -4.152 |
Total Adjustments to Net Income | 0 | -1.228 | -5.925 | -1.773 | 0 |
Income Available to Common Excl. Extra. Items | -92.094 | -70.127 | -49.262 | -12.612 | -4.152 |
Income Available to Common Incl. Extra. Items | -92.094 | -70.127 | -49.262 | -12.612 | -4.152 |
Diluted Net Income | -92.094 | -70.127 | -49.262 | -12.612 | -4.152 |
Diluted Weighted Average Shares | 39.5514 | 33.4332 | 35.6459 | 35.6459 | 35.6459 |
Diluted EPS Excluding Extraordinary Items | -2.32846 | -2.09752 | -1.38198 | -0.35381 | -0.11648 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -2.32846 | -2.09752 | -1.38198 | -0.35381 | -0.11648 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 32.174 | 30.422 | 24.725 | 24.101 | 21.792 |
Selling/General/Admin. Expenses, Total | 8.277 | 8.507 | 7.663 | 7.226 | 6.459 |
Research & Development | 23.897 | 21.915 | 17.062 | 16.875 | 15.333 |
Operating Income | -32.174 | -30.422 | -24.725 | -24.101 | -21.792 |
Interest Income (Expense), Net Non-Operating | 2.195 | 1.989 | 0.815 | 0.313 | 0.133 |
Net Income Before Taxes | -29.979 | -28.433 | -23.91 | -23.788 | -21.659 |
Net Income After Taxes | -29.979 | -28.433 | -23.91 | -23.788 | -21.659 |
Net Income Before Extra. Items | -29.979 | -28.433 | -23.91 | -23.788 | -21.659 |
Net Income | -29.979 | -28.433 | -23.91 | -23.788 | -21.659 |
Total Adjustments to Net Income | 0 | 0 | 0 | ||
Income Available to Common Excl. Extra. Items | -29.979 | -28.433 | -23.91 | -23.788 | -21.659 |
Income Available to Common Incl. Extra. Items | -29.979 | -28.433 | -23.91 | -23.788 | -21.659 |
Diluted Net Income | -29.979 | -28.433 | -23.91 | -23.788 | -21.659 |
Diluted Weighted Average Shares | 67.0331 | 66.2657 | 45.4583 | 38.009 | 37.4371 |
Diluted EPS Excluding Extraordinary Items | -0.44723 | -0.42908 | -0.52598 | -0.62585 | -0.57854 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.44723 | -0.42908 | -0.52598 | -0.62585 | -0.57854 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 236.95 | 214.399 | 49.106 | 7.539 | 0.936 |
Cash and Short Term Investments | 230.245 | 207.469 | 48.539 | 6.466 | 0.929 |
Cash & Equivalents | 57.706 | 119.801 | 48.539 | 6.466 | 0.929 |
Prepaid Expenses | 4.368 | 4.836 | 0.467 | 0.868 | 0.007 |
Other Current Assets, Total | 2.337 | 2.094 | 0.1 | 0.205 | 0 |
Total Assets | 299.366 | 242.59 | 75.908 | 9.826 | 1.007 |
Property/Plant/Equipment, Total - Net | 57.078 | 22.523 | 21.845 | 0.728 | 0.071 |
Property/Plant/Equipment, Total - Gross | 61.688 | 24.607 | 22.571 | 0.849 | 0.101 |
Accumulated Depreciation, Total | -4.61 | -2.084 | -0.726 | -0.121 | -0.03 |
Other Long Term Assets, Total | 5.338 | 5.668 | 4.957 | 1.559 | 0 |
Total Current Liabilities | 13.119 | 10.153 | 10.207 | 2.186 | 7.774 |
Accounts Payable | 1.772 | 1.545 | 2.361 | 0.693 | 0.038 |
Accrued Expenses | 11.161 | 8.174 | 7.123 | 0.938 | 0.577 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 4.459 |
Other Current Liabilities, Total | 0.186 | 0.434 | 0.723 | 0.555 | 2.7 |
Total Liabilities | 48.759 | 26.327 | 27.637 | 2.186 | 7.774 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 250.607 | 216.263 | 48.271 | 7.64 | -6.767 |
Redeemable Preferred Stock | 0 | 107.336 | 25.069 | 0.002 | |
Common Stock | 0.007 | 0.004 | 0.001 | 0 | 0 |
Additional Paid-In Capital | 473.587 | 346.382 | 2.158 | 0.458 | 0.279 |
Retained Earnings (Accumulated Deficit) | -222.217 | -130.123 | -61.224 | -17.887 | -7.048 |
Total Liabilities & Shareholders’ Equity | 299.366 | 242.59 | 75.908 | 9.826 | 1.007 |
Total Common Shares Outstanding | 65.9961 | 37.1747 | 37.1279 | 35.6459 | 35.6459 |
Other Liabilities, Total | 35.64 | 16.174 | 17.43 | ||
Short Term Investments | 172.539 | 87.668 | |||
Preferred Stock - Non Redeemable, Net | 0 | ||||
Unrealized Gain (Loss) | -0.77 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 164.438 | 191.393 | 216.898 | 236.95 | 142.729 |
Cash and Short Term Investments | 160.098 | 186.902 | 210.2 | 230.245 | 136.067 |
Cash & Equivalents | 45.026 | 32.212 | 42.455 | 57.706 | 60.827 |
Prepaid Expenses | 3.673 | 3.952 | 6.239 | 4.368 | 4.891 |
Other Current Assets, Total | 0.667 | 0.539 | 0.459 | 2.337 | 1.771 |
Total Assets | 223.023 | 250.986 | 277.533 | 299.366 | 206.373 |
Property/Plant/Equipment, Total - Net | 52.086 | 53.912 | 55.431 | 57.078 | 58.353 |
Property/Plant/Equipment, Total - Gross | 59.284 | 60.219 | 60.877 | 61.688 | 62.33 |
Accumulated Depreciation, Total | -7.198 | -6.307 | -5.446 | -4.61 | -3.977 |
Other Long Term Assets, Total | 6.499 | 5.681 | 5.204 | 5.338 | 5.291 |
Total Current Liabilities | 15.388 | 12.717 | 12.579 | 13.119 | 11.102 |
Accounts Payable | 1.309 | 1.648 | 3.216 | 1.772 | 0.824 |
Accrued Expenses | 14.017 | 10.947 | 9.198 | 11.161 | 10.045 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.062 | 0.122 | 0.165 | 0.186 | 0.233 |
Total Liabilities | 48.242 | 46.536 | 47.318 | 48.759 | 47.639 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 32.854 | 33.819 | 34.739 | 35.64 | 36.537 |
Total Equity | 174.781 | 204.45 | 230.215 | 250.607 | 158.734 |
Redeemable Preferred Stock | |||||
Common Stock | 0.007 | 0.007 | 0.007 | 0.007 | 0.004 |
Additional Paid-In Capital | 488.873 | 485.508 | 481.032 | 473.587 | 358.215 |
Retained Earnings (Accumulated Deficit) | -313.819 | -280.629 | -250.65 | -222.217 | -198.307 |
Total Liabilities & Shareholders’ Equity | 223.023 | 250.986 | 277.533 | 299.366 | 206.373 |
Total Common Shares Outstanding | 67.7855 | 67.4336 | 66.9349 | 65.9961 | 38.3932 |
Short Term Investments | 115.072 | 154.69 | 167.745 | 172.539 | 75.24 |
Preferred Stock - Non Redeemable, Net | |||||
Unrealized Gain (Loss) | -0.28 | -0.436 | -0.174 | -0.77 | -1.178 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -92.094 | -68.899 | -43.337 | -10.839 | -4.152 |
Cash From Operating Activities | -85.144 | -69.144 | -36.292 | -9.855 | -2.661 |
Cash From Operating Activities | 2.525 | 1.434 | 0.605 | 0.091 | 0.02 |
Non-Cash Items | 17.118 | 7.332 | 2.124 | 0.748 | 1.408 |
Changes in Working Capital | -12.693 | -9.011 | 4.316 | 0.145 | 0.063 |
Cash From Investing Activities | -94.091 | -91.651 | -4.161 | -0.748 | 0 |
Capital Expenditures | -8.462 | -3.894 | -4.161 | -0.748 | 0 |
Cash From Financing Activities | 117.14 | 232.911 | 82.526 | 17.699 | 2.464 |
Issuance (Retirement) of Stock, Net | 117.14 | 235.126 | 82.526 | 17.699 | 0 |
Issuance (Retirement) of Debt, Net | 0 | 2.464 | |||
Net Change in Cash | -62.095 | 72.116 | 42.073 | 7.096 | -0.197 |
Other Investing Cash Flow Items, Total | -85.629 | -87.757 | |||
Financing Cash Flow Items | 0 | -2.215 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -28.433 | -92.094 | -68.184 | -44.396 | -22.737 |
Cash From Operating Activities | -24.268 | -85.144 | -66.798 | -47.896 | -22.904 |
Cash From Operating Activities | 0.837 | 2.525 | 1.893 | 1.001 | 0.426 |
Non-Cash Items | 4.819 | 17.118 | 10.987 | 6.119 | 2.731 |
Changes in Working Capital | -1.491 | -12.693 | -11.494 | -10.62 | -3.324 |
Cash From Investing Activities | 6.498 | -94.091 | 2.945 | -9.757 | -7.055 |
Capital Expenditures | -0.094 | -8.462 | -8.141 | -7.843 | -2.011 |
Cash From Financing Activities | 2.519 | 117.14 | 4.879 | 0.804 | 0.2 |
Financing Cash Flow Items | -0.717 | 0 | 0 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 3.236 | 117.14 | 4.879 | 0.804 | 0.2 |
Net Change in Cash | -15.251 | -62.095 | -58.974 | -56.849 | -29.759 |
Other Investing Cash Flow Items, Total | 6.592 | -85.629 | 11.086 | -1.914 | -5.044 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
RA Capital Management, LP | Hedge Fund | 33.6827 | 22748880 | 0 | 2023-08-10 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 11.2504 | 7598355 | -214681 | 2023-06-30 | LOW |
Paradigm BioCapital Advisors LP | Investment Advisor | 9.5671 | 6461467 | -16532 | 2023-06-30 | MED |
5AM Ventures | Venture Capital | 9.4194 | 6361723 | 0 | 2023-06-30 | MED |
Laurion Capital Management LP | Hedge Fund | 4.7127 | 3182889 | 0 | 2023-06-30 | HIGH |
Invus Public Equities Advisors, LLC | Investment Advisor | 3.98 | 2688015 | -104790 | 2023-06-30 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.908 | 1964007 | 1509942 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.5356 | 1712481 | 133183 | 2023-06-30 | LOW |
Woodline Partners LP | Hedge Fund | 1.6452 | 1111123 | 0 | 2023-06-30 | HIGH |
Johnson & Johnson Innovation-JJDC, Inc. | Venture Capital | 1.5912 | 1074658 | 0 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0696 | 722405 | 406458 | 2023-06-30 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 0.9385 | 633848 | 0 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.9317 | 629286 | 578173 | 2023-06-30 | LOW |
Sarissa Capital Management, L.P. | Hedge Fund | 0.915 | 618000 | 0 | 2023-06-30 | LOW |
Ang (Robert M.D.) | Individual Investor | 0.585 | 395070 | -12657 | 2023-09-01 | LOW |
OUP Management Co., LLC | Venture Capital | 0.5548 | 374714 | 0 | 2023-06-30 | LOW |
Ensign Peak Advisors, Inc. | Foundation | 0.5124 | 346087 | 0 | 2023-06-30 | LOW |
Thrivent Asset Management, LLC | Investment Advisor | 0.4629 | 312652 | -2557 | 2023-06-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.4485 | 302878 | 242434 | 2023-06-30 | LOW |
Bellecapital Partners AG | Investment Advisor/Hedge Fund | 0.1876 | 126726 | 0 | 2023-02-28 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Vor Biopharma Inc. Company profile
About Vor Biopharma Inc
Vor Biopharma Inc is a clinical-stage cell therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solution for patients suffering from hematological malignancies. The Company develops engineered hematopoietic stem cell (eHSC) product candidate, VOR33, VCAR33, which together are the treatment paradigm for acute myeloid leukemia (AML) and other hematological malignancies. The Company’s platform provides treatment for both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates (ADCs), bispecific antibodies and CAR-T cell treatments, including CD33 CAR-T. The Company uses genome engineering technology to remove CD33 surface targets from hematopoietic stem cells (HSCs) to create VOR33. The Company’s eHSCs, such as VOR33, are designed to be used with therapeutics such as VCAR33, that would provide tumor-specific killing.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Vor Biopharma Inc revenues was not reported. Net loss applicable to common stockholders increased 65% to $51.9M. Higher net loss reflects Research and development - Balancing val increase of 67% to $33.2M (expense), General and administrative - Balancing increase from $7M to $14.4M (expense), Stock-based Compensation in R&D increase from $374K to $1.6M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
100 Cambridgepark Drive
Suite 101
CAMBRIDGE
MASSACHUSETTS 02140
US
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com